What is spaxentan/sparsentan?

Sparsentan/Sparsentan is a new non-immunosuppressive single-molecule dual angiotensin and endothelin receptor antagonist that has made significant progress in the treatment of immunoglobulin A nephropathy (IgAN) in recent years. IgAN is the most common primary glomerulonephritis in the world, and its main feature is the deposition of IgA immune complexes on the glomerular membrane, which can lead to damage to the glomerular filtration barrier. As the disease progresses, patients may experience proteinuria and a decrease in kidney function, which may eventually lead to kidney failure.

Current treatment options focus on reducing proteinuria and controlling blood pressure, especially in high-risk patients. However, traditional immunosuppressive treatments are often accompanied by significant side effects, preventing many patients from receiving effective treatment. Therefore, the need to develop new therapeutic drugs is increasingly urgent.

Sparsentan is unique in its dual mechanism of action. It reduces glomerular inflammation and fibrosis by antagonizing endothelin-1 and angiotensin II receptors, thereby reducing proteinuria levels. According to interim results from the PROTECT trial, spaxentan was shown to be more effective than the traditional drug irbesartan in reducing proteinuria, and had an overall favorable safety and tolerability profile. This discovery provides new treatment options for patients with IgAN, especially those at high risk of progression.

In addition, sparsentan'sFDA accelerated approval marks an important milestone in the treatment of kidney disease. This approval not only brings new hope to IgAN patients, but also provides a new direction for the development of related drugs in the future. Researchers and clinicians are optimistic about the prospects of sparsentan and believe that it is of great significance in improving patients' quality of life and delaying disease progression.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC10750480/